Document is current
Any future updates will be listed below
-
Authors
Holmstroem, Rikke Boedker https://orcid.org/0000-0002-5476-9937
Nielsen, Ole Haagen https://orcid.org/0000-0003-4612-8635
Jacobsen, Søren https://orcid.org/0000-0002-5654-4993
Riis, Lene Buhl https://orcid.org/0000-0003-4669-3159
Theile, Susann https://orcid.org/0000-0001-9804-7744
Bjerrum, Jacob Tveiten https://orcid.org/0000-0002-6249-3889
Vilmann, Peter https://orcid.org/0000-0001-7889-1104
Johansen, Julia Sidenius https://orcid.org/0000-0002-4217-6560
Boisen, Mogens Karsbøl https://orcid.org/0000-0002-9891-5449
Eefsen, Rikke Helene Løvendahl https://orcid.org/0000-0003-1421-1792
Marie Svane, Inge https://orcid.org/0000-0002-9451-6037
Nielsen, Dorte Lisbet https://orcid.org/0000-0002-8766-8729
Chen, Inna Markovna https://orcid.org/0000-0003-2891-0762
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03601611 at ClinicalTrials.govnct03293784 at ClinicalTrials.govDocuments that mention this clinical trial
Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management
https://doi.org/10.1136/jitc-2020-000984
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
https://doi.org/10.1136/jitc-2022-005111
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
https://doi.org/10.1136/jitc-2023-006814
nct04940299 at ClinicalTrials.govDocuments that mention this clinical trial
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
https://doi.org/10.1136/jitc-2022-005111
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
https://doi.org/10.1136/annrheumdis-2020-217139
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
https://doi.org/10.1136/jitc-2023-006814
Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications
https://doi.org/10.1136/annrheumdis-2019-216510
nct04258150 at ClinicalTrials.govDocuments that mention this clinical trial
Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications
https://doi.org/10.1136/jitc-2024-011427
Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer
https://doi.org/10.1136/jitc-2024-010612
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
https://doi.org/10.1136/jitc-2022-005111
Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: Clinical outcomes and biomarker analysis.
https://doi.org/10.1200/jco.2024.42.16_suppl.9553
Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition
https://doi.org/10.1136/jitc-2021-003551
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
https://doi.org/10.1136/jitc-2023-006814
816 Selective immune suppression using interleukin-6 blockade in immune related adverse events
https://doi.org/10.1136/jitc-2021-sitc2021.816
Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776
nct04375228 at ClinicalTrials.govDocuments that mention this clinical trial
Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer
https://doi.org/10.1136/jitc-2020-001100
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
https://doi.org/10.1136/jitc-2022-005111
nct04691817 at ClinicalTrials.govDocuments that mention this clinical trial
516 An open-label, phase II multicenter study of rituximab or tocilizumab for steroid-dependent or steroid-refractory immune-related adverse events due to immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2025-sitc2025.0516
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
https://doi.org/10.1136/jitc-2022-005111
Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
https://doi.org/10.1136/jitc-2020-002252
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
https://doi.org/10.1136/jitc-2023-006814
Documents that mention this clinical trial
Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications
https://doi.org/10.1136/jitc-2024-011427
Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer
https://doi.org/10.1136/jitc-2024-010612
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-007310
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
https://doi.org/10.1136/jitc-2022-005111
-
Funding
Funding for this research was provided by:
the Department of Oncology, Copenhagen University Hospital
Gentofte, and the Danish Health Agency "Empowering cancer immunotherapy in Denmark," (DHA 4-1612-236/8)
Bristol-Myers Squibb (CA209-8M8)
- License Information
